HighTower Advisors LLC Raises Stock Position in DaVita Inc. $DVA

Key Points

• HighTower Advisors increased its DaVita stake by 87.7% in the second quarter, owning 13,683 shares valued at approximately $3.04 million. Major investors including Berkshire Hathaway, BlackRock and California State Teachers Retirement System also added positions, with institutions collectively owning 90.12% of the stock.
• Analyst sentiment remains positive, with a consensus rating of “Moderate Buy” and an average price target of $233.43. TD Cowen upgraded the stock to Buy, while Deutsche Bank maintained a Buy rating with a $265 target.
• DaVita exceeded quarterly expectations, reporting $4.02 in EPS versus the $3.88 consensus and $3.55 billion in revenue, up 5.2% year over year. The company issued fiscal 2026 EPS guidance of $14.10–$15.20.

HighTower Advisors LLC grew its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 87.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,683 shares of the company's stock after buying an additional 6,395 shares during the quarter. HighTower Advisors LLC's holdings in DaVita were worth $3,044,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in DVA. Berkshire Hathaway Inc purchased a new stake in DaVita during the second quarter valued at approximately $6,425,269,000. California State Teachers Retirement System increased its position in shares of DaVita by 18,932.5% during the 2nd quarter. California State Teachers Retirement System now owns 8,610,866 shares of the company's stock valued at $1,915,745,000 after purchasing an additional 8,565,623 shares during the last quarter. BlackRock Inc. bought a new position in shares of DaVita during the 2nd quarter valued at approximately $547,520,000. Invesco Ltd. raised its holdings in DaVita by 2.0% during the 3rd quarter. Invesco Ltd. now owns 1,679,248 shares of the company's stock valued at $223,122,000 after buying an additional 32,358 shares during the period. Finally, Morgan Stanley lifted its position in DaVita by 5.1% in the fourth quarter. Morgan Stanley now owns 1,477,045 shares of the company's stock worth $167,807,000 after buying an additional 71,156 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.

Insider Buying and Selling at DaVita

In related news, insider Kathleen Waters sold 15,405 shares of the business's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the sale, the insider owned 109,194 shares in the company, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.90% of the company's stock.

Analyst Ratings Changes

A number of research firms have weighed in on DVA. Oppenheimer set a $220.00 price objective on shares of DaVita in a research report on Friday, August 7th. Raymond James Financial set a $220.00 price target on shares of DaVita in a research note on Friday, August 7th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $265.00 price objective on shares of DaVita in a research report on Wednesday, August 5th. TD Cowen upgraded DaVita from a "hold" rating to a "buy" rating and boosted their target price for the company from $201.00 to $220.00 in a research report on Friday, August 7th. Finally, Zacks Research cut DaVita from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 6th. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $233.43.

DaVita Price Performance

DVA stock opened at $181.56 on Friday. The company has a market capitalization of $11.58 billion, a PE ratio of 14.86, a P/E/G ratio of 0.47 and a beta of 0.83. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $247.49. The firm's 50-day moving average is $204.02 and its 200 day moving average is $185.43.

DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.88 by $0.14. The company had revenue of $3.55 billion during the quarter, compared to analysts' expectations of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The firm's quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the company earned $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Sell-side analysts forecast that DaVita Inc. will post 14.57 EPS for the current fiscal year.

About DaVita

DaVita Inc NYSE: DVA is a healthcare company focused primarily on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis services for people with chronic kidney failure, including in-center hemodialysis and home-based dialysis options. Its services also include clinical care, education, nutrition support and other resources intended to help patients manage kidney disease.

DaVita also provides broader kidney-care services, including chronic kidney disease management, care coordination and support for patients who may be candidates for kidney transplantation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.